Tuberculosis 3: TB Drugs Flashcards

1
Q

1st line drugs for drug susceptible TB

A
  • Isoniazid (H): 300mg
  • Rifampicin (R): 600mg
  • Ethambutol (E): 900mg
  • Pyrazinamide (Z): 1500mg

(for 60kg patients)

Standard regimen:
- ***2 HREZ / 4HR (2 months 4 drugs —> 4 months 2 drugs)
- Supervised daily at chest clinics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

ADR of TB regimen

A
  1. GI
    - mild abdominal discomfort
    - decrease appetite
  2. Cutaneous reaction
  3. Vestibular (Streptomycin)
  4. Liver derangment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

***Serious adverse reactions

A
  1. Hepatitis (H, R, Z)
  2. Retrobulbar neuritis (E)
  3. Thrombocytopenia (R)
  4. Acute renal failure (R)
  5. SJS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

***SE of drugs

A

Isoniazid (H):
- ***Peripheral neuropathy (pyridoxine B6)
- Nervous system damage (tingling / numbness around mouth)
- Hepatitis

Rifampicin (R):
- **Red-orange discolouration of secretions
- **
Enzyme inducer
- ***Easy bruising / Slow blood clotting
- Hepatitis
- Acute renal failure

Ethambutol (E)
- ***Retrobulbar neuritis (not recommended under 5)
—> blurred vision / changed colour vision

Pyrazinamide (Z):
- **Hepatotoxicity
- GI symptoms
- Hepatitis
- **
Gout

Streptomycin:
- ***Affect hearing (Tinnitus)
- Giddiness
- Cutaneous hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GI upset: Guideline

A
  1. Exclude hepatitis with blood tests
    - ALT <3 times upper limit
    - Total Bilirubin <2 times upper limit

(ALT (more specific to liver), AST: Parenchymal enzyme
ALP, GGT (more specific to liver): Ductal enzyme)

  1. Administer drugs with food
  2. Anti-emetic
    - ***avoid antacids (∵ ↓ absorption of Isoniazid + Rifampicin)
  3. Daily regimens if symptoms related to bulk of medications in intermittent regimens
    - Fixed dose combination may help
  4. No split doses —> result in suboptimal drug levels —> acquired resistance
  5. Medication at bedtime may help (if self-administered treatment)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Non-petechial rash: Guideline

A
  1. Exclude other causes
  2. Mild: Symptomatic relief with **Antihistamines / **Topical steroid
    - watch out for progression + mucosal involvement
  3. Moderate - Severe: ***Suspend treatment, Antihistamine, Systemic steroid (if life-threatening)
    - reintroduce drugs later with caution
  4. Consult dermatologist if necessary
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hepatotoxicity: Guideline

A
  1. Identify underlying risk factors (e.g. alcoholics, chronic viral hepatitis)
  2. Withhold treatment if ALT >3 times / Total Bilirubin >2 times upper limit
  3. If Hepatitis suspected clinically, may ***withhold treatment until blood results available
  4. ***Reintroduce drugs when ALT return to normal / baseline
  5. If Extensive TB, earlier reintroduction may be considered when ALT on ↓ trend / clinically stable
    - Non-hepatotoxic interim regimen may be considered
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk factors for Drug-induced Hepatotoxicity

A
  1. Old patients
  2. Low BMI
  3. Malnutrition
  4. Pre-existing liver disease: Alcoholic liver diseases, Chronic viral hepatitis (HBV, HCV etc.)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Prognosis of Drug-induced Hepatotoxicity

A
  • Liver function return to normal in most cases if drugs stopped early
  • No specific treatment
  • Hepatoprotective agent ***no use
  • Complications: ***Fulminant hepatic failure (may require liver transplantation)
  • Bilirubin >2 times ULN with associated transaminase rise is dangerous sign
    —> Severe hepatotoxicity
    —> Can lead to mortality if drug not stopped
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ocular toxicity

A

Ethambutol

Retrobulbar neuritis:
- Bilateral progressive **painless visual blurring
- **
↓ Colour perception
- ***Central vision most commonly affected
- Usually delayed onset (months after initiation)
- Progressive (most typical) / Acute / Chronic

Prognosis:
- Generally **reversible
- Dependent on **
dose + duration

Treatment:
- Therapy discontinuation (stop progression + allow recovery)
- Stop Isoniazid also 6 weeks after stopping Ethambutol if no vision improvement

Location recommendation:
- Keep 15mg/kg daily OR 30mg/kg three times weekly
- Discontinue ethambutol as soon as drug-susceptibility shows no use
- 15mg/kg three times weekly (instead of daily) if GFR < 30 ml/min
- **
Warn patients to report change in vision immediately
- Check patients weights at least monthly
- Any risk factors for optic neuropathy / need to take > 8 weeks —> Check vision monthly (esp. Colour vision)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Rifampicin-induced AKI

A

Mechanism not well established
- Type 2 / 3 hypersensitivity reaction induced by Rifampicin Ag
—> Anti-Rifampicin Ab form immune complexes
—> deposit in renal vessels, glomerular endothelium, interstitium

Prognosis:
- Generally favourable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Thrombocytopenia

A

Rifampicin

Intermittent therapy > Daily therapy

Mechanism:
- Presence of Antiplatelet Ab —> Thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Peripheral neuropathy

A

Isoniazid

  • ***Dose dependent
  • Uncommon at 5 mg/kg/day
  • More common in elderly, DM, alcoholism, slow acetylator phenotype, HIV, renal failure

Prophylaxis:
- Pyridoxine 10-20mg daily

Treatment:
- Pyridoxine 50-100mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cutaneous adverse reaction

A

Spectrum of disease:
- mild maculopapular rash
- acute generalised exanthematous pustulosis
- DRESS (drug reaction with eosinophilia + systemic symptoms)
- epidermal necrolysis (SJS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Rifampicin drug interactions

A

CYP450 inducer (most powerful)
- 2B6, 2C8, 2C9, 2C19, 3A4, 3A5, 3A7, 3A, 2C
—> ↑ metabolism of many drugs

—> Rifampicin Inductive effect&raquo_space; Isoniazid Inhibitory effect
—> overall should ↓ dose of affected drugs

Drugs affected:
1. Oral hypoglycaemic drugs (***sulphonylureas)

  1. **PI, NNRTI (HIV drugs)
    - ART should be started in all HIV patients with TB regardless of CD4
    - initiate TB treatment first —> ART asap within 8 weeks (2 weeks if very low CD4)
    - Use **
    Efavirenz + 2 NRTI (if concurrent HIV + TB)
  2. Warfarin
    - 5-7 days after initiation —> 5-7 days after withdrawal
  3. Phenytoin
  4. Oral contraceptives
    - recommend female patients of reproductive age take extra contraceptive methods
  5. Immunosuppressants (Corticosteroid, Cyclosporine, Tacrolimus)
    - Addison’s disease should ↑ Corticosteroid dosage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Isoniazid drug interactions

A

Potent ***Inhibitor of CYP isozymes
—> ↑ conc of some drugs to toxicity level

—> Rifampicin Inductive effect&raquo_space; Isoniazid Inhibitory effect
—> overall should ↓ dose of affected drugs

Drugs affected:
1. Phenytoin
2. Carbamazepine
3. Benzodiazepines metabolised by ***oxidation: Diazepam, Triazolam (but not those metabolised by conjugation: Oxazepam)

17
Q

Levofloxacin

A

**Antacids containing Mg, Al, Sucralfate, Metal cations (e.g. Fe)
—> Interfere GI absorption of Levofloxacin
—> **
2 hours before / after Levofloxacin

18
Q

Directly Observed Therapy (DOT)

A

Strongly recommended by WHO, IUATLD
—> Most effective measure to control TB

Patients provided necessary support to complete whole course of treatment
- avoid treatment failure, drug resistance, spread of disease

5 components:
1. Sustained political and financial commitment
2. Diagnosis by quality ensured sputum-smear microscopy
3. Standardised short-course Anti-TB treatment under DOT
4. Regular, uninterrupted supply of high quality Anti-TB drugs
5. Standardised recording + reporting —> keep track of each patient, monitor overall programme performance

19
Q

Contact tracing

A
  1. Identify source of infection
  2. Identify contacts who actually have active TB
  3. Identify uninfected contacts —> eligible for BCG vaccination
  4. Educate contacts about TB —> seek medical advice early in case of developing S/S of TB
  5. Identify contacts who have LTBI —> consider preventive Rex

Based on:
1. Infectiousness of index case
2. Degree of closeness of contact
3. Susceptibility of contact people

WHO recommendation:
Conduct for house-hold + close contacts when ***index case:
1. Sputum smear-positive pulmonary TB
2. People living with HIV (PLHIV)
3. Child < 5 age

Risk of progression:
- 5-10% of infected will develop active TB
- 10% for HIV +ve
- other medical conditions: silicosis, DM, alcoholism etc.

20
Q

***Drug resistant TB

A
  1. Mono-resistance (ONE 1st line drug only)
  2. Rifampicin-resistance RR (Rifampicin with / without resistance to other drugs)
  3. Poly-resistance (>=ONE 1st line drug other than H + R)
  4. ***MDR (Both H + R)
  5. ***XDR (MDR + Any Fluoroquinolone + >=ONE of three 2nd line injectable: Capreomycin, Kanamycin, Amikacin)
21
Q

Development of resistance

A

Spontaneous mutation
—> Selection (∵ inadequate / improper treatment)
—> Transmission

***Never add a single drug to failing regimen (要加就要加幾隻 —> 確保殺曬全部菌)

22
Q

Conventional methods for drug susceptibility testing

A

Isolation of mycobacteria from specimen
—> Identification of mycobacterium TB complex
—> In vitro testing of strain susceptibility to Anti-TB drugs

Slow + Cumbersome
- Patients may be inappropriately treated during this time
- Drug resistant strains may continue to spread
- Amplification of resistance may occur

23
Q

Molecular drug resistance test

A

Detect major gene mutations associated with resistance

  1. Xpert MTB/RIF
  2. Ultra
  3. Line probe assays (LPA)
    - 1st line LPAs: test for resistance to H + R
    - 2nd line LPAs: test for resistance for Fluoroquinolone, Injectable
24
Q

Treatment of Drug-resistant TB

A

Group 1: 1st line oral agents (HREZ)
Group 2: Injectable (Kanamycin, Amikacin, Capreomycin, Streptomycin)
Group 3: Levofloxacin, Moxifloxacin
Group 4: Cycloserine, Para-aminosalicylic acid (PAS)
Group 5: Clofazimine, Linezolid, Augmentin

25
Q

Linezolid

A
  • Treatment of serious infection by ***Gram +ve bacteria
  • demonstrated in vitro activity against M TB

Problems:
1. Short-term use: Unlikely to achieve stable cure
2. Long-term use: Anaemia, Thrombocytopenia, Peripheral / Optic neuropathy

—> Optimal dosing schedule remains unclear
—> Adverse events can be significantly ↓ by ↓ dosage

26
Q

Bedaquiline

A
  • Diarylquinoline
  • Inhibits mycobacterial ***ATP synthase —> interfere with bacterial energy metabolism
  • 1st novel drug conditionally approved for MDR-TB
  • NO cross-resistance with other drugs

Problems:
1. QT prolongation: other drugs (e.g. Fluoroquinolone, Clofazimine, Delamanid, Macrolide)
2. Hepatotoxicity: ↑ ALT
3. CYP3A4 metabolism —> drug interaction
4. Extremely long t1/2

27
Q

Delamanid

A
  • Nitroimidazopyran (derivative of Metronidazole)
  • Inhibit Mycolic acid biosynthesis
28
Q

MDR-TB treatment

A

Outdated:
Group A: Fluoroquinolone
Group B: 2nd line injectable
Group C: Other core 2nd line agents (e.g Linezolid, Clofazimine)
Group D: Add-on agents
- Bedaquiline
- Delamanid

Treatment (5 total drugs):
- Pyrazinamide
- 1 from group A
- 1 from group B
- >=2 from group C
(Add-on agent to bring to 5 total drugs if others cannot)

Newer recommendation:
Group A: Levofloxacin / Moxifloxacin + Bedaquiline + Linezolid

Group B: Add
- Clofazimine
and/or
- Cycloserine/Terizidone

Group C: Add to complete regimen or when Group A, B cannot be used
- Ethambutol
- Pyrazinamide
- Delamanid
- Amikacin / Streptomycin
- Ethionamide / Prothionamide
- Para-aminosalicylic acid
- Imipenem-cilastatin / Meropenem

29
Q

Shorter MDR-TB regimen

A

4-6 months:
- Kanamycin
- Moxifloxacin
- Prothionamide
- Clofazimine
- Pyrazinamide
- High dose Isoniazid
- Ethambutol

Then

5 months:
- Moxifloxacin
- Clofazimine
- Pyrazinamide
- Ethambutol

30
Q

Isoniazid resistant TB

A

Treatment (RLEZ regimen):
- R
- E
- Z
- Levofloxacin

Duration:
- 6 months

***NOT recommended to add Streptomycin / Injectables

31
Q

Latent TB infection

A
  1. Isoniazid
  2. Isoniazid + Rifapentine
  3. Rifampicin
32
Q

Vaccination to prevent TB

A

BCG vaccine: only licensed vaccine

  • Slow decline in TB incidence
    —> need for much more effective vaccine
  • Effective against **meningitis + **disseminated TB in children
  • ***NOT prevent primary infection
  • ***NOT prevent reactivation of latent pulmonary infection